Kiromic Competitors

Delisted . USA . 
Stock . Kiromic Biopharma
KRBPDelisted Stock  USD 2.68  0.07  2.55%   
Kiromic Biopharma competes with Quoin Pharmaceuticals, Allarity Therapeutics, Virax Biolabs, Biodexa Pharmaceticals, and Zura Bio; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Kiromic Biopharma competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Kiromic Biopharma to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Kiromic Biopharma competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
2.682.682.68
Details
Intrinsic
Valuation
LowRealHigh
2.552.552.95
Details
Naive
Forecast
LowNextHigh
2.652.652.65
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
2.532.883.22
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Kiromic Biopharma. Your research has to be compared to or analyzed against Kiromic Biopharma's peers to derive any actionable benefits. When done correctly, Kiromic Biopharma's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Kiromic Biopharma.

Kiromic Biopharma Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Kiromic Biopharma and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Kiromic and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Kiromic Biopharma does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
BDRX
+ 0.93
ALLR
CYTO
+ 0.93
ALLR
VRAX
+ 0.92
ALLR
BDRX
+ 0.92
VRAX
IMMX
+ 0.9
VRAX
CYTO
+ 0.9
BDRX
  
High negative correlations   
ZURA
- 0.28
ALLR
IMMX
- 0.24
ZURA
CYTO
- 0.24
ZURA
ZURA
- 0.23
VRAX
CNSP
- 0.17
ZURA
ZURA
- 0.16
BDRX

Risk-Adjusted Indicators

There is a big difference between Kiromic Stock performing well and Kiromic Biopharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Kiromic Biopharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
QNRX  6.23  0.43  0.07  0.37  6.74 
(8.82)
 17.65 
(9.68)
 74.46 
ALLR  5.08 (1.88) 0.00 (2.04) 0.00 
 0.00 
 10.85 
(16.11)
 41.48 
VRAX  6.06 (1.37) 0.00  6.06  0.00 
 0.00 
 9.65 
(13.45)
 61.28 
BDRX  6.49 (1.65) 0.00 (0.45) 0.00 
 0.00 
 11.91 
(17.24)
 97.78 
ZURA  3.80 (0.37) 0.00 (0.08) 0.00 
 0.00 
 7.95 
(7.94)
 30.69 
CYTO  3.45 (1.13) 0.00 (20.57) 0.00 
 0.00 
 6.98 
(10.87)
 22.81 
IMMX  3.80 (0.45) 0.00 (0.26) 0.00 
 0.00 
 7.06 
(8.22)
 32.68 
ENVB  3.21 (0.64) 0.00 (1.76) 0.00 
 0.00 
 6.25 
(7.50)
 28.33 
PALI  3.53 (0.52) 0.00 (1.96) 0.00 
 0.00 
 5.97 
(8.55)
 24.25 
CNSP  4.84 (0.34) 0.00 (0.09) 0.00 
 0.00 
 9.09 
(11.76)
 39.29 
All Fundamental Data

Kiromic Biopharma Competitive Analysis

The better you understand Kiromic Biopharma competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Kiromic Biopharma's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Kiromic Biopharma's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
KRBP QNRX ALLR VRAX BDRX ZURA CYTO IMMX ENVB PALI
 2.55 
 2.68 
Kiromic
 1.59 
 0.62 
Quoin
 5.88 
 1.26 
Allarity
 3.19 
 1.94 
Virax
 14.29 
 4.40 
Biodexa
 1.03 
 2.93 
Zura
 7.32 
 0.44 
Altamira
 7.69 
 1.68 
Immix
 2.86 
 0.34 
Enveric
 0.41 
 2.44 
Palisade
Market Volatility
(90 Days Market Risk)
Very steady
Out of control
Abnormally volatile
Extremely Dangerous
Dangerous
Very risky
Out of control
Dangerous
Out of control
Very risky
Market Performance
(90 Days Performance)
Very Weak
Insignificant
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Average
Very High
Low
Very High
Below Average
Below Average
Average
Very High
Very High
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Fairly Valued
Fairly Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Buy
Hold
Strong Sell
Strong Buy
Strong Buy
Not Available
Buy
Buy
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Current Ratio
1.35
0.96
0.88
0.04
N/A
N/A
0.77
19.53
8.33
2.59
Net Asset
11.97 M
12.17 M
11.86 M
5.48 M
10.54 M
100.84 M
7.69 M
19.93 M
4.3 M
14.05 M
Profit Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
EBITDA
(29.44 M)
(9.27 M)
(12.08 M)
(6.61 M)
(6.46 M)
(60.56 M)
(1.35 M)
(16.14 M)
(17.14 M)
(12.28 M)
Current Valuation
9.55 M
(7.18 M)
(11.54 M)
5.06 M
(3.36 M)
191.65 M
2.02 M
27.61 M
(3.72 M)
(3.95 M)
Price To Book
15.11
0.58
0.43
1.57
0.23
1.25
0.26
2.63
0.85
0.56
Operating Margin
N/A
N/A
N/A
-42.54
-79.31
N/A
N/A
N/A
N/A
N/A
Retained Earnings
(101.95 M)
(46.2 M)
(94.45 M)
(18.53 M)
(144.77 M)
(103.49 M)
(18.05 M)
(53.41 M)
(96.5 M)
(121.51 M)
Current Asset
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Beta
0.16
1.89
0.29
1.93
1.44
0.14
2.44
0.1
0.47
1.33
Number Of Employees
31
4
5
17
21
14
10
14
7
9
Shares Outstanding
1.18 M
5.05 M
1.41 M
4.34 M
580.84 K
63.77 M
3.78 M
27.51 M
9.94 M
1.33 M
Cash Flow From Operations
(23.75 M)
(7.86 M)
(12.74 M)
(6.25 M)
(6.83 M)
(15.05 M)
(11.51 M)
(11.37 M)
(14.09 M)
(11.13 M)
Total Debt
9.41 M
3.52 K
1.3 M
224.3 K
464 K
21.29 M
99.66 K
3.72 M
2.34 M
369 K
Return On Equity
-11.3
-1.0
-1.22
-0.96
-0.97
-0.37
-3.69
-1.04
-2.06
-1.1
Z Score
-21.07
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
-0.92
-0.36
-0.48
-0.5
-0.38
-0.21
-0.57
-0.57
-0.8
-0.59
Number Of Shares Shorted
45.74 K
478.43 K
179.44 K
446.54 K
13.76 K
1.75 M
31.09 K
434.94 K
330.22 K
43.11 K
Book Value Per Share
-5.35
5.74
16.98
2.09
24.07
2.34
2.37
0.82
0.71
18.3
Current Liabilities
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Asset
11.97 M
12.17 M
11.86 M
5.48 M
10.54 M
100.84 M
7.69 M
19.93 M
4.3 M
14.05 M
Debt To Equity
0.21
0.47
0.11
N/A
N/A
N/A
0.045
0.002
0.005
0.23
Short Ratio
0.93
0.2
0.3
0.11
0.03
5.43
0.6
2.94
0.31
0.29
Target Price
N/A
4.5
5.0
20.0
156.43
15.0
4.5
7.0
8.32
30.33
Shares Owned By Institutions
68.0
5.88
1.2
5.37
39.82
53.29
3.13
17.64
7.05
3.57
Market Capitalization
2.15 M
3.13 M
2.06 M
8.42 M
2.56 M
295.78 M
1.65 M
46.21 M
3.35 M
3.73 M
Price To Earning
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.16
Price To Sales
N/A
N/A
N/A
53.85
30.79
N/A
0.64
N/A
0.0831
14.03
Net Income
(34.73 M)
(8.69 M)
(11.9 M)
(6.74 M)
(7.08 M)
(60.56 M)
(3.87 M)
(15.6 M)
(17.29 M)
(12.3 M)
Earnings Per Share
-39.68
-3.66
-10.98
-3.36
-75.92
0.57
1.82
-0.84
-2.42
-13.26
Shares Owned By Insiders
3.91
2.44
12.3
7.06
10.16
31.87
0.52
40.09
6.92
1.88
Revenue
N/A
N/A
N/A
156.42 K
381 K
N/A
N/A
N/A
N/A
250 K
Working Capital
(11.59 M)
7.7 M
(12.2 M)
4.21 M
1.46 M
80.54 M
334.24 K
16.07 M
1.24 M
10.74 M
Cash And Equivalents
6.51 M
2.69 M
7.73 M
21.76 K
N/A
N/A
984.19 K
18.4 M
18.01 M
5 M
Cash Per Share
0.41
0.56
0.75
N/A
N/A
N/A
1.29
1.32
11.44
0.23
Gross Profit
N/A
N/A
(36.35 M)
(1.36 K)
(4.41 M)
N/A
(2.18 M)
N/A
8.15 M
N/A
Day Typical Price
2.73
0.63
1.25
1.91
5.35
2.94
0.43
1.74
0.33
2.56
Accumulation Distribution
0.0769
0.0615
0.0625
0.0714
0.44
0.0268
0.0889
0.13
0.0882
0.19
Market Facilitation Index
0.22
0.04
0.08
0.14
3.29
0.08
0.04
0.24
0.03
0.54
Daily Balance Of Power
(0.32)
(0.25)
0.875
0.4286
0.1672
0.375
0.75
(0.58)
(0.33)
0.0185
Period Momentum Indicator
(0.07)
(0.01)
0.07
0.06
0.55
0.03
0.03
(0.14)
(0.01)
0.01
Rate Of Daily Change
0.97
0.98
1.06
1.03
1.14
1.01
1.07
0.92
0.97
1.0
Day Median Price
2.75
0.63
1.24
1.89
5.82
2.95
0.43
1.77
0.33
2.62
Price Action Indicator
(0.10)
(0.01)
0.055
0.08
(1.15)
(0.01)
0.025
(0.16)
0.01
(0.18)
Relative Strength Index
43.49
47.7
30.88
38.44
36.33
35.06
34.74
47.97
35.17
39.13
Coefficient Of Variation
(5,719)
1794.55
(418.26)
(690.83)
(871.18)
(3,156)
(420.43)
(1,714)
(788.53)
(1,011)
Mean Deviation
6.0
6.23
5.08
6.06
6.49
3.8
3.45
3.8
3.21
3.53
Jensen Alpha
(0.24)
0.4303
(1.88)
(1.37)
(1.65)
(0.37)
(1.13)
(0.45)
(0.64)
(0.52)
Total Risk Alpha
(1.37)
(0.81)
(2.77)
(2.64)
(2.88)
(0.82)
(1.73)
(1.04)
(1.22)
(1.13)
Sortino Ratio
N/A
0.0652
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Downside Variance
N/A
55.81
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Standard Deviation
9.22
10.71
7.47
9.56
11.69
5.02
4.67
5.47
4.69
4.88
Kurtosis
8.42
13.12
2.36
12.18
18.7
1.79
0.8162
4.25
5.88
3.24
Potential Upside
12.04
17.65
10.85
9.65
11.91
7.95
6.98
7.06
6.25
5.97
Treynor Ratio
(0.24)
0.3732
(2.04)
6.06
(0.45)
(0.08)
(20.57)
(0.26)
(1.76)
(1.96)
Maximum Drawdown
65.24
74.46
41.48
61.28
97.78
30.69
22.81
32.68
28.33
24.25
Variance
84.96
114.69
55.78
91.33
136.56
25.23
21.82
29.96
21.96
23.86
Market Risk Adjusted Performance
(0.23)
0.3832
(2.03)
6.07
(0.44)
(0.07)
(20.56)
(0.25)
(1.75)
(1.95)
Risk Adjusted Performance
(0)
0.0518
(0.17)
(0.10)
(0.08)
(0.02)
(0.17)
(0.04)
(0.09)
(0.07)
Skewness
1.87
2.57
(0.47)
2.39
2.85
(0.48)
(0.34)
1.34
1.65
0.5299
Semi Deviation
N/A
6.74
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Information Ratio
(0.03)
0.0455
(0.25)
(0.16)
(0.12)
(0.05)
(0.26)
(0.08)
(0.15)
(0.12)
Value At Risk
(10.96)
(9.68)
(16.11)
(13.45)
(17.24)
(7.94)
(10.87)
(8.22)
(7.50)
(8.55)
Expected Short fall
N/A
(8.82)
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Downside Deviation
N/A
7.47
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Semi Variance
N/A
45.43
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

Kiromic Biopharma Competition Performance Charts

Five steps to successful analysis of Kiromic Biopharma Competition

Kiromic Biopharma's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Kiromic Biopharma in relation to its competition. Kiromic Biopharma's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Kiromic Biopharma in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Kiromic Biopharma's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Kiromic Biopharma, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Kiromic Biopharma position

In addition to having Kiromic Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Target Risk ETFs Thematic Idea Now

Target Risk ETFs
Target Risk ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Target Risk ETFs theme has 32 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Target Risk ETFs Theme or any other thematic opportunities.
View All  Next Launch
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Other Consideration for investing in Kiromic Stock

If you are still planning to invest in Kiromic Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kiromic Biopharma's history and understand the potential risks before investing.
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY